SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - February 2025

Sanofi: Information concerning the total number of voting rights and shares - February 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of €2,467,152,142

Registered office : 46, avenue de la Grande Armée - 75017 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date





Total number of

issued shares





Number of real

voting rights

(excluding treasury shares)		Theoretical number of

voting rights

(including treasury shares)*
February 28, 20251,263,132,7211,354,221,5041,396,197,561

* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

e-mail:











Attachment



EN
03/04/2025

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi’s respiratory pipeline advances with new data in...

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthmaItepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025. Sanofi today shared new progress...

April 15, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Le portefeuille de traitements contre les malad...

Communiqué de presse : Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO De nouvelles données de phase II démontrent l’efficacité de l’amlitélimab dans le traitement de l’asthme inflammatoire hétérogèneLe lunsekimig cible désormais la rhinosinusite chronique et la BPCO en plus de l’asthme Les études...

April 15, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate...

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib...

April 8, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Publication dans le NEJM de données de phase II...

Communiqué de presse : Publication dans le NEJM de données de phase III illustrant le bénéfice du tolebrutinib sur la progression du handicap dans la sclérose en plaques Publication dans le NEJM de données de phase III illustrant le bénéfice du tolebrutinib sur la progression du handicap dans la sclérose en plaques Les résultats de l’étude de phase III HERCULES montrent que le tolebrutinib retarde la progression du handicap chez les personnes présentant une sclérose en plaques secondairement progressive sans poussées. Le tolebrutinib a le potentiel d’être le premier médicament pouvant mo...

April 8, 2025 1 EN
Free Trial
SAN SANOFI

Sanofi: 1 director

A director at Sanofi bought 500 shares at 110.050USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...

04/04/25 April 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch